Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 6/20 | 0.37 |
| ▸ | ACACA | Q13085 | 6/20 | 0.37 |
| ▸ | GRM5 | P41594 | 5/20 | 0.34 |
| ▸ | REV1 | Q9UBZ9 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | TACR1 | P25103 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | FNTA | P49354 | 2/20 | 0.32 |
| ▸ | FNTB | P49356 | 2/20 | 0.32 |
| ▸ | TACR3 | P29371 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4982838 | 0.91 | GRM5 (0.38) | GRM5LMNA | |
| SCHEMBL4988438 | 0.89 | KEAP1 (0.40) | GRM5LMNA | |
| SCHEMBL4985602 | 0.87 | KEAP1 (0.42) | GRM5LMNA | |
| SCHEMBL4990989 | 0.87 | GRM5 (0.35) | GRM5 | |
| SCHEMBL4988240 | 0.76 | CNR2 (0.42) | RIPK1 | |
| SCHEMBL5013858 | 0.74 | GRM5 (0.33) | GRM5 | |
| SCHEMBL4988256 | 0.74 | ADORA2A (0.46) | GRM5LMNA | |
| SCHEMBL4988610 | 0.74 | CGAS (0.36) | GRM5PARP1LMNA | |
| SCHEMBL4980898 | 0.74 | DPP4 (0.34) | PARP1TACR3 | |
| SCHEMBL4985064 | 0.74 | CNR2 (0.36) | GRM5FNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | RENOVIS, INC. | 2008-02-14 | — | — | US | claimed |
| US-7297700-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. (US) | 2007-11-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | P2RX7, P2RX3, P2RX2 | ACACB 4129/4885ACACA 3957/4885GRM5 231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.